CTOs on the Move

EpicentRx Inc

www.epicentrx.com

 
EpicentRx is a patient-driven immuno-oncology company with minimally toxic therapies that work across diverse patient populations and tumor types for the best possible quality of life during treatment.
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million
  • www.epicentrx.com
  • 11099 North Torrey Pines Road Suite 160
    La Jolla, CA USA 92037
  • Phone: 858.947.6635

Executives

Name Title Contact Details

Funding

EpicentRx Inc raised $35M on 11/13/2019

Similar Companies

Assurex Health

Assurex Health is a personalized medicine company that specializes in helping physicians determine the right medication for individual patients who have Behavioral Health disorders. The GeneSight analysis is based on pharmacogenomics, the study of the genetic factors that influence an individual`s response to drug treatments.

Opus Genetics

Opus Genetics is a groundbreaking gene therapy company for inherited retinal diseases with a unique model and purpose. Backed by Foundation Fighting Blindness`s venture arm, the RD Fund, Opus combines unparalleled insight and commitment to patient need with wholly owned programs in numerous orphan retinal diseases.

Biocompare

Biocompare is a South San Francisco, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

William Gallagher Associates

William Gallagher Associates is a Boston, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Principia Biopharma

Principia Biopharma is a privately-held biopharmaceutical company focused on the discovery and development of best-in-class small molecule drugs for autoimmune diseases and cancer. The company uses its proprietary technology, licensed from the University of California San Francisco, to enable a new approach to making small molecules that are potent, safe and have antibody-like specificity. Principia raised $40 million in a Series A round of financing from a leading group of healthcare investors, including New Leaf Venture Partners, OrbiMed Advisors, Morgenthaler Ventures, SROne and Mission Bay Capital.